18F-FCH-PET has superior sensitivity than ultrasound or sestamibi for parathyroid localization: Study

The results of the study are as follows:

· Among the total 101 patients, 18F-fluorocholine positron emission tomography localized at least 1 candidate lesion in 93% of patients overall and in 91% of patients with previously negative imaging, leading to a change in preoperative strategy in 60% of patients.

· Of 76 patients who underwent parathyroidectomy, 58 (77%) had laboratory data at least 6 months postoperatively, with 55/58 patients (95%) demonstrating cure.

· 18F-fluorocholine positron emission tomography successfully guided curative surgery in 48/58 (83%) patients, compared with 20/57 (35%) based on ultrasound and 13/55 (24%) based on sestamibi.

· In a location-based analysis, the sensitivity of 18F-fluorocholine positron emission tomography (88.9%) outperformed both ultrasound (37.1%) and sestamibi (27.5%), as well as ultrasound and sestamibi combined (47.8%).

The researchers concluded that among the first cohort in the United States the use of 18F-fluorocholine positron emission tomography for parathyroid localization confirm its utility in a challenging cohort, with better sensitivity than ultrasound or sestamibi.

Reference:

Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism by Graves C et. al published in the Surgery.

DOI: https://doi.org/10.1016/j.surg.2021.05.056